---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-028183"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T00:12:56.574283+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo Q2 net loss $114.5M, revenue down 77% YoY; impairments of $51.3M

## Summary
- Net loss $114.5M ($0.66/sh) vs $43.2M ($0.29/sh) YoY, driven by $51.3M intangible asset impairment.
- Revenue $6.8M vs $29.4M YoY, down 77% due to terminations of Novartis, Biogen, Sanofi deals.
- Total GAAP op expenses $130.4M (incl. $51.3M impairment); non-GAAP op expenses $72.3M.
- Cash & marketable securities $182.1M at June 30; raised $15.1M via ATM; cash runway >12 months.
- Updated 2023 GAAP op expense guidance $378-398M; non-GAAP unchanged at $240-260M.

## SEC filing metadata
- accession: 0001628280-23-028183
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828023028183/0001628280-23-028183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828023028183/sgmo-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-028183
- JSON: https://secwatch.observer/filing/0001628280-23-028183.json
- Plain text: https://secwatch.observer/filing/0001628280-23-028183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.